Summary:
This Phase 3 clinical trial (TRAILBLAZER-ALZ 3) will test whether donanemab, also known as LY3002813, effectively reduces the risk of cognitive decline in people at risk for Alzheimer's disease. Participants will be randomly assigned to receive injections of the study drug or a placebo. This study will last up to three and half years. Researchers will measure cognitive function over time and track the immune response and the levels of study drug in the participants' blood.
Qualified Participants Must:
• Be aged 65 to 80 years
•
Normal cognition based on cognitive test
•
Reliable study partner and a backup partner who are familiar with the participant's overall function and behavior, such as day-to-day activities and cognitive abilites
•
Adequate literacy, vision, and hearing for neuropsychological testing at study screening
Qualified Participants May Receive:
Compensation for time and travel upon qualifications into the study.